Clinical features and outcomes of cytomegalovirus retinitis after transplantation

Transplant Infectious Disease

Volumn 10, Issue 1, 2008, Pages 13-18

  Eid, A J ^a   Bakri, S J ^a   Kijpittayarit, S ^a   Razonable, R R ^a  

^a Mayo Clinic   (United States)

Author keywords

Bone marrow transplant; Cytomegalovirus; Ganciclovir; Immunosuppression; Kidney transplantation; Outcomes; Retinitis; Solid organ transplant; Transplantation

Indexed keywords

FOSCARNET; GANCICLOVIR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETINITIS; UVEITIS; VISUAL ACUITY;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; FEMALE; FOSCARNET; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 38649114995     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2007.00241.x     Document Type: Article

References (15)

1. Paya CV, Razonable RR. Cytomegalovirus infection after solid organ transplantation. In : Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections. Philadelphia : Lippincott Williams and Wilkins, 2003 : 298.
2. Egbert PR, Pollard RB, Gallagher JG, Merigan TC. Cytomegalovirus retinitis in immunosuppressed hosts. II. Ocular manifestations. Ann Intern Med 1980 93 : 664 670.
3. Jabs DA, Van Natta ML, Kempen JH, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2002 133 : 48 61.
4. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology 2004 111 : 2232 2239.
5. Kempen JH, Jabs DA, Dunn JP, West SK, Tonascia J. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immunodeficiency syndrome. Arch Ophthalmol 2001 119 : 33 40.
6. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK. Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis. Am J Ophthalmol 2005 139 : 1028 1034.
7. Lin DY, Warren JF, Lazzeroni LC, Wolitz RA, Mansour SE. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV infected patients: natural history and clinical predictors. Retina 2002 22 : 268 277.
8. Kuo IC, Kempen JH, Dunn JP, Vogelsang G, Jabs DA. Clinical characteristics and outcomes of cytomegalovirus retinitis in persons without human immunodeficiency virus infection. Am J Ophthalmol 2004 138 : 338 346.
9. Wagle AM, Biswas J, Gopal L, Madhavan HN. Clinical profile and immunological status of cytomegalovirus retinitis in organ transplant recipients. Indian J Ophthalmol 2002 50 : 115 121.
10. Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis 2001 32 : 214 219.
11. Holland GN, Buhles WC Jr., Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy Study Group. Arch Ophthalmol 1989 107 : 1759 1766.
12. Paya CV, Wold AD, Ilstrup DM, Smith TF. Evaluation of number of shell vial cell cultures per clinical specimen for rapid diagnosis of cytomegalovirus infection. J Clin Microbiol 1988 26 : 198 200.
13. Razonable RR, Brown RA, Espy MJ, et al. Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems. J Clin Microbiol 2001 39 : 4472 4476.
14. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 11th Annual Meeting of the IHMF (International Herpes Management Forum) 27-29 February 2004. Herpes 2004 11 : 77 86.
15. Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther 2004 2 : 27 41.